Physician profile
Sarah E M Pardue
NPI 1821612292
$1,283.73
in general payments reported to CMS, 2019-2025
24 companies · $814 in 2025
The $814 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $17.54 · 2024: $452 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,283.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $165.94 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.57 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $95.93 | 2024-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $86.19 | 2024-2025 | Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $79.72 | 2024-2025 | Rexulti |
| Pfizer INC. | $71.46 | 2024-2025 | |
| Dynavax Technologies Corporation | $67.83 | 2024-2025 | Heplisav-B |
| Grifols USA, LLC | $56.99 | 2025 | Prolastin-C Liquid |
| Novo Nordisk INC | $53.43 | 2025 | Wegovy |
| Astellas Pharma US INC | $52.46 | 2024-2025 | Veozah |
| Corcept Therapeutics | $46.78 | 2025 | Korlym |
| Mylan Specialty L.P. | $45.35 | 2024 | Yupelri |
| Esperion Therapeutics, INC. | $44.50 | 2025 | Nexletol |
| Abbvie INC. | $41.93 | 2025 | |
| Medtronic, INC. | $31.67 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $31.32 | 2025 | |
| Exact Sciences Corporation | $29.46 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Dexcom, INC. | $24.40 | 2024 | Dexcom G6 Transmitter |
| Tolmar, INC. | $23.78 | 2025 | Jatenzo |
| Inspire Medical Systems, INC. | $19.56 | 2025 | Inspire |
| Philips North America LLC | $17.54 | 2023 | |
| Abbott Laboratories | $16.56 | 2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.83 | 2025 | Caplyta |
| Amgen INC. | $13.53 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Pardue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.